Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial

Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial

Expressed by cancer stem cells of various epithelial cell origins and hepatocellular carcinoma (HCC), CD133 is an attractive therapeutic target for HCC. The marker CD133 is highly expressed in endothelial progenitor cells (EPC). EPCs circulate in increased numbers in the peripheral blood of patients...

Full description

Bibliographic Details
Main Authors: Hanren Dai, Chuan Tong, Daiwei Shi, Meixia Chen, Yelei Guo, Deyun Chen, Xiao Han, Hua Wang, Yao Wang, Pingping Shen
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:OncoImmunology
Subjects:
hepatocellular carcinoma
chimeric antigen receptor
cd133
biomarker
Online Access:http://dx.doi.org/10.1080/2162402X.2020.1846926

Internet

http://dx.doi.org/10.1080/2162402X.2020.1846926

Similar Items